Nogueira Miguel, Vender Ron, Torres Tiago
Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.
Department of Dermatology, McMaster University, Hamilton, ON, Canada.
Drugs Context. 2020 May 14;9. doi: 10.7573/dic.2020-4-10. eCollection 2020.
The pandemic known as coronavirus disease-19 (COVID-19) has quickly spread worldwide, with a significant impact on lives all over the world. The complexity related to the new coronavirus and the clinical syndrome it causes is not yet fully understood. The impact of COVID-19 on patients with psoriasis under biologic agents is continuously being observed in this rapidly changing pandemic. A case-by-case evaluation must be made by dermatologists, and the final decision should be discussed and decided by both the patient and the specialist. Observations reveal that immunosuppressive therapy may have a role in the treatment of this virus, placing emphasis on the scenario of safety through maintenance of therapy with biologic agents, especially when there are no signs or symptoms related to the infection or contact with an infected patient.
被称为冠状病毒病-19（COVID-19）的大流行已迅速在全球蔓延，对世界各地的生命造成了重大影响。与新型冠状病毒及其引发的临床综合征相关的复杂性尚未完全明了。在这场迅速变化的大流行中，COVID-19对接受生物制剂治疗的银屑病患者的影响仍在持续观察中。皮肤科医生必须进行逐案评估，最终决定应由患者和专家共同讨论并做出。观察结果显示，免疫抑制疗法可能在这种病毒的治疗中发挥作用，这突出了通过维持生物制剂治疗来确保安全的情况，尤其是在没有与感染相关的体征或症状或未接触过感染患者的情况下。
